Home > Services > Clinical Research Studies > Clinical Trials Details
<< Back to Results
Olaparib treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy.
Contact Phone: 218-786-3308 | 1-844-681-7944
Locations: Essentia Health Cancer Centers
For more information about a financial conflict of interest (FCOI) or to review the Essentia Health FCOI policy, click here.